Inhibition of amyloid beta-induced synaptotoxicity by a pentapeptide derived from the glycine zipper region of the neurotoxic peptide

Neurobiology of Aging

Volumn 34, Issue 12, 2013, Pages 2805-2814

  Peters, Christian ^a   Fernandez Perez, Eduardo J ^a   Burgos, Carlos F ^a   Espinoza, María P ^a   Castillo, Carolina ^a   Urrutia, Juan C ^a   Streltsov, Victor A ^b   Opazo, Carlos ^a,c   Aguayo, Luis G ^a  

^a UNIVERSITY OF CONCEPCIÓN   (Chile)

^b CSIRO   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Alzheimer; Beta Amyloid; Oligomers; Pore; Synaptic Toxicity

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; GLYCYLLEUCYLMETHIONYLVALYLGLYCINE; POLYPEPTIDE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG STRUCTURE; FLUORESCENCE RESONANCE ENERGY TRANSFER; LIPID MEMBRANE; MOLECULAR DOCKING; NEUROPROTECTION; NEUROTOXICITY; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN AGGREGATION;

ALZHEIMER; BETA AMYLOID; OLIGOMERS; PORE; SYNAPTIC TOXICITY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BRAIN; CALCIUM; CELL MEMBRANE; CELLS, CULTURED; GLYCINE; HUMANS; MEMBRANE LIPIDS; MOLECULAR TARGETED THERAPY; NEUROPROTECTIVE AGENTS; OLIGOPEPTIDES; SYNAPTIC TRANSMISSION; SYNAPTIC VESICLES;

EID: 84884149468     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2013.06.001     Document Type: Article

References (48)

1. Andersen O.S., Koeppe R.E., Roux B. Gramicidin channels. IEEE Trans. Nanobioscience 2005, 4:10-20.
2. Arispe N., Diaz J.C., Flora M. Efficiency of histidine-associating compounds for blocking the alzheimer's Abeta channel activity and cytotoxicity. Biophys. J. 2008, 95:4879-4889.
3. Arispe N., Rojas E., Pollard H.B. Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc. Natl. Acad. Sci. U.S.A 1993, 90:567-571.
4. Armstrong A.H., Chen J., McKoy A.F., Hecht M.H. Mutations that replace aromatic side chains promote aggregation of the Alzheimer's Abeta peptide. Biochemistry 2011, 50:4058-4067.
5. Avila M.E., Sepulveda F.J., Burgos C.F., Moraga-Cid G., Parodi J., Moon R.T., Aguayo L.G., Opazo C., De Ferrari G.V. Canonical Wnt3a modulates intracellular calcium and enhances excitatory neurotransmission in hippocampal neurons. J.Biol. Chem. 2010, 285:18939-18947.
6. Baglioni S., Casamenti F., Bucciantini M., Luheshi L.M., Taddei N., Chiti F., Dobson C.M., Stefani M. Prefibrillar amyloid aggregates could be generic toxins in higher organisms. J.Neurosci. 2006, 26:8160-8167.
7. Barnham K.J., Cappai R., Beyreuther K., Masters C.L., Hill A.F. Delineating common molecular mechanisms in Alzheimer's and prion diseases. Trends Biochem. Sci. 2006, 31:465-472.
8. Bidwell G.L. Peptides for cancer therapy: a drug-development opportunity and a drug-delivery challenge. Ther. Deliv. 2012, 3:609-621.
9. Carrasco M.A., Castro P.A., Sepulveda F.J., Cuevas M., Tapia J.C., Izaurieta P., van Zundert B., Aguayo L.G. Anti-homeostatic synaptic plasticity of glycine receptor function after chronic strychnine in developing cultured mouse spinal neurons. J.Neurochem. 2007, 100:1143-1154.
10. Chen R., Li L., Weng Z. ZDOCK: an initial-stage protein-docking algorithm. Proteins 2003, 52:80-87.
11. Comeau S.R., Gatchell D.W., Vajda S., Camacho C.J. ClusPro: a fully automated algorithm for protein-protein docking. Nucleic Acids Res. 2004, 32:W96-W99.
12. Crescenzi O., Tomaselli S., Guerrini R., Salvadori S., D'Ursi A.M., Temussi P.A., Picone D. Solution structure of the Alzheimer amyloid beta-peptide (1-42) in an apolar microenvironment. Similarity with a virus fusion domain. Eur. J. Biochem. 2002, 269:5642-5648.
13. Ding T.T., Lee S.J., Rochet J.C., Lansbury P.T. Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry 2002, 41:10209-10217.
14. Dodel R., Neff F., Noelker C., Pul R., Du Y., Bacher M., Oertel W. Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence. Drugs 2010, 70:513-528.
15. Edwards C.M., Cohen M.A., Bloom S.R. Peptides as drugs. QJM 1999, 92:1-4.
16. Glabe C.G., Kayed R. Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology 2006, 66:S74-S78.
17. Gozes I., Giladi E., Pinhasov A., Bardea A., Brenneman D.E. Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze. J.Pharmacol. Exp. Ther. 2000, 293:1091-1098.
18. Gu X., Olson E.C., Spitzer N.C. Spontaneous neuronal calcium spikes and waves during early differentiation. J.Neurosci. 1994, 14:6325-6335.
19. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell. Biol. 2007, 8:101-112.
20. Hafner J.H., Cheung C.L., Woolley A.T., Lieber C.M. Structural and functional imaging with carbon nanotube AFM probes. Prog. Biophys. Mol. Biol. 2001, 77:73-110.
21. Harmeier A., Wozny C., Rost B.R., Munter L.M., Hua H., Georgiev O., Beyermann M., Hildebrand P.W., Weise C., Schaffner W., Schmitz D., Multhaup G. Role of amyloid-glycine 33 in oligomerization, toxicity, and neuronal plasticity. J.Neurosci. 2009, 29:7582-7590.
22. Herrero E.P., Alonso M.J., Csaba N. Polymer-based oral peptide nanomedicines. Ther. Deliv. 2012, 3:657-668.
23. Hung L.W., Ciccotosto G.D., Giannakis E., Tew D.J., Perez K., Masters C.L., Cappai R., Wade J.D., Barnham K.J. Amyloid-beta peptide (Abeta) neurotoxicity is modulated by the rate of peptide aggregation: Abeta dimers and trimers correlate with neurotoxicity. J.Neurosci. 2008, 28:11950-11958.
24. Jang, H., Zheng J., Lal R., Nussinov R. New structures help the modeling of toxic amyloidbeta ion channels. Trends Biochem. Sci. 2008, 33:91-100.
25. Jarrett J.T., Lansbury P.T. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie?. Cell 1993, 73:1055-1058.
26. Kawahara M., Kuroda Y., Arispe N., Rojas E. Alzheimer's beta-amyloid, human islet amylin, and prion protein fragment evoke intracellular free calcium elevations by a common mechanism in a hypothalamic GnRH neuronal cell line. J.Biol. Chem. 2000, 275:14077-14083.
27. Kayed R., Pensalfini A., Margol L., Sokolov Y., Sarsoza F., Head E., Hall J., Glabe C. Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. J.Biol. Chem. 2009, 284:4230-4237.
28. Kienlen-Campard P., Tasiaux B., Van Hees J., Li M., Huysseune S., Sato T., Fei J.Z., Aimoto S., Courtoy P.J., Smith S.O., Constantinescu S.N., Octave J.N. Amyloidogenic processing but not amyloid precursor protein (APP) intracellular C-terminal domain production requires a precisely oriented APP dimer assembled by transmembrane GXXXG motifs. J.Biol. Chem. 2008, 283:7733-7744.
29. Kim I.D., Shin J.H., Lee H.K., Jin Y.C., Lee J.K. Intranasal delivery of HMGB1-binding heptamer peptide confers a robust neuroprotection in the postischemic brain. Neurosci. Lett. 2012, 525:179-183.
30. Kim S. Transmembrane glycine zippers: physiological and pathological roles in membrane proteins. Proc. Natl. Acad. Sci. U.S.A 2005, 102:14278-14283.
31. Kim W., Hecht M.H. Generic hydrophobic residues are sufficient to promote aggregation of the Alzheimer's Abeta42 peptide. Proc. Natl. Acad. Sci. U.S.A 2006, 103:15824-15829.
32. Lasagna-Reeves C.A., Glabe C.G., Kayed R. Amyloid- annular protofibrils evade fibrillar fate in Alzheimer disease brain. J.Biol. Chem. 2011, 286:22122-22130.
33. Luhrs T., Ritter C., Adrian M., Riek-Loher D., Bohrmann B., Dobeli H., Schubert D., Riek R. 3D structure of Alzheimer's amyloid-beta(1-42) fibrils. Proc. Natl. Acad. Sci. U.S.A 2005, 102:17342-17347.
34. Miller Y., Ma B., Nussinov R. Polymorphism in Alzheimer Abeta amyloid organization reflects conformational selection in a rugged energy landscape. Chem. Rev. 2010, 110:4820-4838.
35. Munter L.M., Voigt P., Harmeier A., Kaden D., Gottschalk K.E., Weise C., Pipkorn R., Schaefer M., Langosch D., Multhaup G. GxxxG motifs within the amyloid precursor protein transmembrane sequence are critical for the etiology of Aβ42. EMBO J. 2007, 26:1702-1712.
36. Nakamura M., Shishido N., Nunomura A., Smith M.A., Perry G., Hayashi Y., Nakayama K., Hayashi T. Three histidine residues of amyloid-beta peptide control the redox activity of copper and iron. Biochemistry 2007, 46:12737-12743.
37. Negi S.S., Kolokoltsov A.A., Schein C.H., Davey R.A., Braun W. Determining functionally important amino acid residues of the E1 protein of Venezuelan equine encephalitis virus. J.Mol. Model. 2006, 12:921-929.
38. Parodi J., Sepulveda F.J., Roa J., Opazo C., Inestrosa N.C., Aguayo L.G. β-amyloid causes depletion of synaptic vesicles leading to neurotransmission failure. J.Biol. Chem. 2009, 285:2506-2514.
39. Peters C., Munoz B., Sepulveda F.J., Urrutia J., Quiroz M., Luza S., De Ferrari G.V., Aguayo L.G., Opazo C. Biphasic effects of copper on neurotransmission in rat hippocampal neurons. J.Neurochem. 2011, 119:78-88.
40. Pettersen E.F., Goddard T.D., Huang C.C., Couch G.S., Greenblatt D.M., Meng E.C., Ferrin T.E. UCSF Chimera-a visualization system for exploratory research and analysis. J.Comput. Chem. 2004, 25:1605-1612.
41. Sepulveda F.J., Parodi J., Peoples R.W., Opazo C., Aguayo L.G. Synaptotoxicity of Alzheimer beta amyloid can be explained by its membrane perforating property. PLoS One 2010, 5:e11820.
42. Singer S.J., Nicolson G.L. The fluid mosaic model of the structure of cell membranes. Science 1972, 175:720-731.
43. Stephan A., Laroche S., Davis S. Generation of aggregated beta-amyloid in the rat hippocampus impairs synaptic transmission and plasticity and causes memory deficits. J.Neurosci. 2001, 21:5703-5714.
44. Streltsov V.A., Varghese J.N., Masters C.L., Nuttall S.D. Crystal structure of the amyloid-p3 fragment provides a model for oligomer formation in Alzheimer's disease. J.Neurosci. 2011, 31:1419-1426.
45. Strodel B., Lee J.W., Whittleston C.S., Wales D.J. Transmembrane structures for Alzheimer's Abeta(1-42) oligomers. J.Am. Chem. Soc. 2010, 132:13300-13312.
46. Tjernberg L.O., Naslund J., Lindqvist F., Johansson J., Karlstrom A.R., Thyberg J., Terenius L., Nordstedt C. Arrest of beta-amyloid fibril formation by a pentapeptide ligand. J.Biol. Chem. 1996, 271:8545-8548.
47. Wurth C., Guimard N.K., Hecht M.H. Mutations that reduce aggregation of the Alzheimer's Aβ42 peptide: an unbiased search for the sequence determinants of Aβ amyloidogenesis. J.Mol. Biol. 2002, 319:1279-1290.
48. Yu L., Edalji R., Harlan J.E., Holzman T.F., Lopez A.P., Labkovsky B., Hillen H., Barghorn S., Ebert U., Richardson P.L., Miesbauer L., Solomon L., Bartley D., Walter K., Johnson R.W., Hajduk P.J., Olejniczak E.T. Structural characterization of a soluble amyloid β-peptide oligomer. Biochemistry 2009, 48:1870-1877.